Pharminent

Bristol-Myers Squibb’s Opdivo approved for Hodgkin lymphoma in Europe

Bristol-Myers Squibb has secured approval from the European Commission for Opdivo (nivolumab) to treat adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. http://regulatoryaffairs.pharmaceutical-business-review.com/news/bristol-myers-squibbs-opdivo-approved-for-hodgkin-lymphoma-in-europe-231116-5676797

Filed under: Cancer, Immunotherapy